Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Agilent to Acquire Biocare Medical in $950 Million All-Cash Deal

📈 Agilent Technologies agreed to acquire privately held Biocare Medical for $950 million in an all-cash deal.

🎯 The acquisition aims to strengthen Agilent's position in cancer diagnostics and laboratory technologies.

📊 Biocare, based in the San Francisco Bay Area, generated over $90 million in revenue in 2025.

🔬 Biocare develops specialized instruments, antibodies, and reagents for both research and clinical settings.

🤝 The transaction will integrate Biocare into Agilent's Life Sciences and Diagnostics Markets Group.

💸 Management expects the deal to become accretive to earnings per share approximately 12 months after closing.

⏰ CEO Padraig McDonnell stated the acquisition will accelerate innovation and support long-term shareholder value.

🧾 Biocare is being sold by an investor group led by Excellere Partners and GHO Capital Partners.

⚖️ Financial adviser Jefferies Financial Group and legal adviser Ropes & Gray represented the sellers in the deal.

🏦 Agilent was advised by Barclays and Sullivan & Cromwell for this transaction.

🔗 Combining portfolios could expand Agilent's capabilities to serve a broader range of laboratories.

📅 The acquisition is expected to close by the end of Agilent's fiscal fourth quarter, ending Oct. 31.

🏆 This marks Agilent's largest acquisition since its 2019 purchase of BioTek Instruments for $1.17 billion.

📉 Agilent shares have fallen about 15% this year with a current market value of roughly $32.5 billion.

Bullish Signals
  • Agilent Technologies agreed to acquire privately held Biocare Medical in an all-cash deal valued at $950 million, strengthening its position in cancer diagnostics and laboratory technologies.
  • The transaction is expected to become accretive to earnings per share roughly 12 months after closing, signaling financial benefits for shareholders.
  • CEO Padraig McDonnell stated the acquisition will accelerate innovation while supporting long-term value creation for shareholders.
  • Biocare generated more than $90 million in revenue in 2025 and offers more than 300 specialized antibodies alongside a range of reagents and laboratory instruments.
  • The deal expands Agilent's analytical and clinical technologies portfolio by combining its capabilities with Biocare's antibody, reagent and instrument offerings to serve a broader set of laboratories.
  • The transaction is expected to close by the end of Agilent's fiscal fourth quarter ending Oct. 31.
  • This acquisition represents the company's largest acquisition since its $1.17 billion purchase of BioTek Instruments in 2019 and follows the $925 million acquisition of Biovectra in 2024, indicating an aggressive growth strategy.
  • Agilent Technologies agreed to acquire privately held Biocare Medical in an all-cash deal valued at $950 million, strengthening its position in cancer diagnostics and laboratory technologies.
  • The transaction is expected to become accretive to earnings per share roughly 12 months after closing, signaling financial benefits for shareholders.
  • CEO Padraig McDonnell stated the acquisition will accelerate innovation while supporting long-term value creation for shareholders.
  • Biocare generated more than $90 million in revenue in 2025 and offers more than 300 specialized antibodies alongside a range of reagents and laboratory instruments.
  • The deal expands Agilent's analytical and clinical technologies portfolio by combining its capabilities with Biocare's antibody, reagent and instrument offerings to serve a broader set of laboratories.
  • The transaction is expected to close by the end of Agilent's fiscal fourth quarter ending Oct. 31.
  • This acquisition represents the company's largest acquisition since its $1.17 billion purchase of BioTek Instruments in 2019 and follows the $925 million acquisition of Biovectra in 2024, indicating an aggressive growth strategy.
Risk Factors
  • Agilent Technologies has agreed to acquire Biocare Medical for $950 million in all-cash, which represents a significant capital outlay that could impact liquidity.
  • The article warns that GuruFocus detected 2 Warning Signs associated with UBS regarding the company's valuation or financial health.
  • Shares have fallen about 15% this year despite the acquisition announcement, indicating potential market skepticism or broader sector concerns.
  • This is Agilent's largest acquisition since its $1.17 billion purchase of BioTek Instruments in 2019 and follows a $925 million acquisition of Biovectra in 2024, suggesting aggressive growth spending that may affect near-term earnings.
  • Integration of Biocare into the Life Sciences and Diagnostics Markets Group will not become accretive to earnings per share until roughly 12 months after closing, delaying financial benefits.
  • Acquisition costs will be paid in all-cash, increasing leverage or cash burn without immediate revenue recognition from the deal.
Full Analysis
Agilent Technologies (NYSE:A) has entered into an agreement to acquire privately held Biocare Medical in an all-cash transaction valued at $950 million. The acquisition is designed to strengthen Agilent's position within cancer diagnostics and laboratory technologies, with Biocare set to integrate into Agilent's Life Sciences and Diagnostics Markets Group. Company Chief Executive Officer Padraig McDonnell stated that the deal aims to accelerate innovation while supporting long-term value creation for shareholders. According to a company statement reviewed by Bloomberg News, the transaction is expected to become accretive to earnings per share approximately 12 months after closing. Biocare Medical, headquartered in the San Francisco Bay Area, specializes in instruments and materials used in cancer research, having generated more than $90 million in revenue in 2025. The company's portfolio includes over 300 specialized antibodies, reagents, and laboratory instruments utilized in both research and clinical environments. The deal is being executed by an investor group led by Excellere Partners and GHO Capital Partners, with financial advice from Jefferies Financial Group and legal counsel from Ropes & Gray, while Agilent retained Barclays and Sullivan & Cromwell for advisory and legal support respectively. This transaction represents Agilent's largest acquisition since the $1.17 billion purchase of BioTek Instruments in 2019, following the $925 million acquisition of Biovectra in 2024. The strategic rationale for the acquisition includes expanding Agilent's analytical and clinical technologies portfolio by combining its existing capabilities with Biocare's offerings in antibodies, reagents, and instruments, potentially allowing the company to serve a broader set of laboratories. The deal is projected to close by the end of Agilent's fiscal fourth quarter, which concludes on October 31. Despite the acquisition activity, Agilent shares have declined approximately 15% this year, leaving the company with a market value of roughly $32.5 billion.